Cytoseek's cell membrane augmentation technology enables them to add new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability.
The University of Bristol spin-out have secured £1.1 million for ground-breaking 'supercharged' cell therapies to treat solid tumours.
|Imophoron||Imophoron is an innovative vaccine technology start-up based at Unit DX in Bristol. Their researchers have engineered a synthetic protein scaffold named the ADDomer®, which tricks the immune system into developing antibodies against the Chikungunya virus. Unlike most vaccines, their Chikungunya vaccine candidate can be produced and stored without refrigeration.|
Rosa biotech combine protein design with machine learning to develop a sensing platform that mimics mammals' sense of smell to detect chronic diseases.
The spin-out have raised £760k from Angel Investors to commercialise this biosensing technology.
Zentraxa use bioengineering to produce peptides, specifically 'BioBetters', with predictable properties that are tailored to purpose.
The spin-out have secured £500k investment to commercialise their proprietary technological platform, Zentide, to produce biological adhesives for the heathcare sector.